Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit
PR Newswire
SAN FRANCISCO, Oct. 8, 2026
SAN FRANCISCO, Oct. 8, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.
Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering (IPO) on or about February 13, 2025, and/or purchased or acquired Aardvark securities between February 13, 2025 and May 14, 2026 (the Class Period), are encouraged to contact our firm now.
Key Case Details & Important Deadlines
- Lead Plaintiff Motion Deadline: October 13, 2026
- Visit: www.hbsslaw.com/aard
- Contact the Firm Now: AARD@hbsslaw.com
844-916-0895
Watch our video on the Aardvark investigation: youtu.be/pY5E36QoCqo
What is the Lawsuit About?
The complaint alleges that Aardvark Therapeutics, a clinical-stage biopharmaceutical company focused on developing small-molecule therapies targeting bitter taste receptors (TAS2Rs) such as ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS), made materially false and misleading statements and/or failed to disclose critical information.
Specifically, the action points out that the offering documents and defendants failed to disclose:
- That ARD-101 was significantly less safe than defendants had led investors to believe;
- That unexpected, reversible cardiac observations (such as QRS prolongation) occurred during trials at above-target doses; and
- Consequently, Aardvark's clinical, regulatory, and commercial prospects—including the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE)—were materially overstated.
The Truth Emerges: Voluntarily Pause and FDA Clinical Hold
- February 27, 2026: Aardvark announced it was voluntarily pausing its Phase 3 HERO trial due to "reversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study." Following this news, Aardvark's stock price plummeted over 56%.
- May 14, 2026: Aardvark announced that the U.S. Food and Drug Administration (FDA) placed a full clinical hold on its investigational new drug application (IND) for ARD-101, halting all ongoing studies under the IND, including the Phase 3 HERO trial and OLE trial. Aardvark's stock price fell another 32.1%.
Hagens Berman's Investigation
"We're investigating the suit's allegations, including that Aardvark allegedly misled investors about ARD-101's development, its safety and efficacy," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the claims in the pending suit.
What Can Aardvark Investors Do?
If you are a class member who suffered losses on Aardvark securities, you have until October 13, 2026, to ask the Court to appoint you as Lead Plaintiff for the class. The firm welcomes AARD investors to contact the firm to discuss their legal rights and potential recovery options.
- Submit Your Information to Hagens Berman
- Contact an Attorney: AARD@hbsslaw.com
844-916-0895
If you'd like more information and answers to frequently asked questions about the firm's Aardvark investigation, read more »
Whistleblowers: Persons with non-public information regarding Aardvark Therapeutics should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email AARD@hbsslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
SOURCE Hagens Berman Sobol Shapiro LLP
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
United States